

COVID-19 Vaccine Formulation Update

On Monday, September 11, 2023 the FDA approved reformulated COVID-19 Vaccines, Spikevax (COVID-19 Vaccine, mRNA 2023-2024 Formula) made by Moderna and Comirnaty (COVID-19 Vaccine, mRNA 2023-2024 Formula) made by Pfizer-BioNTech. Approval of Spikevax (Moderna) and Comirnaty (Pfizer-BioNTech) updates the previous bivalent vaccine to a monovalent vaccine that is expected to more closely target the current circulating variants of COVID-19.

What you need to know:

- The previous bivalent formulations of Moderna and Pfizer-BioNTech COVID-19 vaccine are no longer authorized for use in the United States
- The 2023-2024 mRNA vaccines made by Moderna (Spikevax) and Pfizer-BioNTech (Comirnaty) are FDA approved for individuals 12 years of age and older
- The 2023-2024 mRNA vaccines made by Moderna (Spikevax) and Pfizer-BioNTech (Comirnaty) are authorized under emergency use for individuals 6 months through 11 years old
- CDC recommends all individuals 6 months and older receive at least 1 dose of the updated 2023-2024 mRNA COVID-19 vaccination
- Availability of the mRNA vaccines should be available in the coming weeks

Below is a link for more information regarding the updated formulation from the FDA:

[FDA Announcement on COVID-19 Formulation Update 091123](#)

If you have any further questions regarding the COVID-19 Vaccine, please reach out to education@synchronyhs.com.